Fiche publication
Date publication
janvier 1997
Journal
Anti-cancer drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VIGNERON Céline
Tous les auteurs :
Bossu E, A'Amar O, Parache RM, Notter D, Labrude P, Vigneron C, Guillemin F
Lien Pubmed
Résumé
Two major steps in our study on the treatment of skin tumors by photochemotherapy (PCT) were the development of a skin tumor model in hairless mice by chemical carcinogenesis and by the use fluorescence spectroscopy, a semi-quantitative and non-invasive method, to determine the time after i.p. injection of photosensitizer when the tumor/normal skin ratio is the highest. Carcinogenesis provided mice bearing many benign papillomas and these were used to determine the tumor/normal skin ratios of two photosensitizers by fluorescence spectroscopy. Hematoporphyrin derivative (HpD) (5 mg/kg body weight) and m-tetra(hydroxyphenyl)-chlorin (m-THPC) (0.3 mg/kg body weight) were injected, and fluorescence measured at 4, 8, 24, 48, 72 and 96 h after injection. The tumor/normal skin ratio was 6.2 for HpD and 5.1 for m-THPC. The times required to reach these ratios were 48 h for HpD and 72 h for m-THPC. Published reports indicate that m-THPC gives a much higher tumor/normal skin ratio than HpD. These results must be confirmed by organic extraction. Photodynamic therapy with the same doses of HpD and m-THPC used in this pharmacokinetic study must also be carried out to compare the toxicities of the two photosensitizers and to determine which is best for this type of tumor.
Mots clés
Animals, Antineoplastic Agents, pharmacokinetics, Female, Hematoporphyrin Derivative, pharmacokinetics, Mesoporphyrins, pharmacokinetics, Mice, Mice, Hairless, Neoplasm Transplantation, Papilloma, drug therapy, Photochemotherapy, Skin, pathology, Skin Neoplasms, drug therapy, Spectrometry, Fluorescence
Référence
Anticancer Drugs. 1997 Jan;8(1):67-72
